Online inquiry

IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11433MR)

This product GTTS-WQ11433MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets F gene. The antibody can be applied in Respiratory Syncytial Virus (RSV) infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID P03420
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11433MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10689MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ14944MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ7284MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ15443MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ4380MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ5824MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ14658MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ555MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 4D5-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW